The study is both qualitative and quantitative, gathering patient's perceptions of HCV treatment benefits before and after HCV treatment by administering surveys and conducting in-depth qualitative patient interviews. The study seeks to understand all anticipated and actual benefits patients perceive before and after viral eradication.

This study employs a mixed methods (qualitative and quantitative) pre-post study design utilizing in-depth qualitative interviews and patient reported outcome surveys. Pre-treatment surveys and interviews will be conducted before HCV therapy commences to understand all potential psychological, social, physical and medical consequences perceived to be related to HCV and the patients' anticipation (hope for) of improvements in these factors after viral eradication. Post-treatment surveys and interviews will occur 4 to 8 months after treatment ends to examine long-term treatment benefits, i.e., changes in HCV-related factors, such as symptoms, functioning, and health status.

Inclusion Criteria:

• Age 21 or older
• English-speaking
• Any genotype
• Any treatment duration (e.g. 8, 12, or 24 weeks)
• Has been written a prescription for a sofosbuvir (SOF)-containing regimen.

Exclusion Criteria:

• Currently listed for liver transplant; post-liver transplant

Patients with Hepatitis C